ClinicalTrials.gg
TerminatedNCT03958955Updated Mar 6, 2025Results posted

Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus.

A Phase 2 interventional study of Delgocitinib cream and Delgocitinib cream vehicle in Discoid Lupus Erythematosus, sponsored by LEO Pharma. Terminated at 19 sites in 4 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-03-06.

Sponsored by LEO Pharma · Phase 2, Interventional, and Treatment

Why this study was terminated
Terminated due to recruitment challenges.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Lupus Erythematosus, Discoid with a site in Germany — 3 open to participants now, 7 under way, 5 of them phase 3. Lupus Erythematosus, Discoid · Germany.

Enrollment
10th of 12
27 · median 73
Started
2019
the only one that year
Phase 2
5 of 13
none open now
Registered
4th of 13
by date
Lead sponsor
1 of 13
LEO Pharma

Among the 13 studies in Lupus Erythematosus, Discoid with a site in Germany, this one is the 10th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2019, is one of 5 in phase 2, and was the 4th registered.

Lupus Erythematosus, Discoid

42 studies on the registry are indexed under Lupus Erythematosus, Discoid; 7 are open to participants now.

Browse Lupus Erythematosus, Discoid studies →

Open to participants now

3 of the 13 studies in Lupus Erythematosus, Discoid with a site in Germany are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 5 Lupus Erythematosus, Discoid studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Lupus Erythematosus, Discoid with a site in Germany, or all of them as a file.
02

Study summary

This was a double-blind, multi-centre, randomised, vehicle-controlled, within-subject phase 2a trial. The trial was designed to establish the efficacy and safety of delgocitinib cream in the treatment of adult subjects with discoid lupus erythematosus (DLE).

03

Conditions studied

  • Discoid Lupus Erythematosus
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Histopathological findings (current or previous) consistent with clinical diagnosis of DLE.
  • Unequivocal clinical diagnosis of 2 active DLE target lesions that were \<6 months old and amenable for clinical evaluation. This included lesions located on the scalp if they fulfilled all lesion-specific eligibility criteria.
  • Target lesion IGA score of at least moderate severity (≥3) at screening and baseline.
  • Target lesion erythema score ≥2 at screening and baseline.

Main Exclusion Criteria:

  • Target lesion dyspigmentation score of 2 at screening or baseline.
  • Target lesion scarring/atrophy score of 2 at screening or baseline.
  • Target lesion scarring alopecia score of >0 in scalp lesions at screening or baseline.
  • Medical history of systemic lupus erythematosus (SLE) with organ involvement (American College of Rheumatology SLE classification criteria no. 6 to 9) including SLE-related pleuritis or pericarditis (by clinical evaluation and ), and neurologic, renal, and/or other major SLE-related organ system involvement. SLE joint involvement was acceptable.
  • Subjects with unstable or significant SLE disease activity findings that would, by its progressive nature and/or severity, interfere with the trial evaluation, completion, and/or procedures per the investigator's discretion.
  • Other skin conditions at screening or baseline that would interfere with the evaluation of DLE.
  • /immunomodulating therapy with e.g. methotrexate, cyclosporine, azathioprine, retinoids (both topical and systemic), or dapsone within 4 weeks prior to baseline.
  • Systemic prednisolone >7.5 mg/day or changed dose within 4 weeks prior to baseline (nasal and inhaled were allowed).
  • Treatment with the following medications:

    • Oral antimalarial treatment with hydroxychloroquine >6.5 mg/kg body weight/day, or chloroquine >4 mg/kg body weight/day, or changed dose within 12 weeks prior to baseline.
    • Quinacrine combined with either hydroxychloroquine or chloroquine within 12 weeks prior to baseline.
    • Drugs known to interact with antimalarials (e.g. digoxin, cimetidine) within 12 weeks prior to baseline.
  • Treatment with topical corticosteroids, calcineurin inhibitors, and phosphodiesterase-4 (PDE-4) inhibitors within 2 weeks prior to baseline.
  • Use of systemic antibiotics or cutaneously applied antibiotics on the target lesions within 2 weeks prior to baseline.
  • Ultraviolet (UV) therapy within 2 weeks prior to baseline.
  • Any procedure impairing the skin barrier (e.g. incision) within 2 cm from the border of any of the target lesions within 4 weeks prior to baseline.
  • Receipt of live (attenuated) vaccines within 4 weeks prior to baseline.
  • Treatment with any marketed biological therapy or biologic agents:

    • Any cell-depleting agents including but not limited to rituximab: within 6 months prior to baseline, or until lymphocyte count returned to normal, whichever was longer.
    • Other biologics: within 3 months or 5 half-lives, whichever was longer, prior to baseline.
  • Unstable or fluctuating use of tobacco within 1 month prior to screening which, in the opinion of the investigator, could affect the natural course of the disease and thus affect the evaluation of the treatment.
  • History of any active skin infection within 1 week prior to baseline.
  • Clinically significant infection within 4 weeks prior to baseline which, in the opinion of the investigator, could compromise the safety of the subject in the trial, interfere with evaluation of the IMP, or reduce the subject's ability to participate in the trial. Clinically significant infections are defined as:

    • A systemic infection.
    • A serious skin infection requiring parenteral (intravenous or intramuscular) antibiotics, antiviral, or antifungal medication.
  • Tuberculosis requiring treatment within 12 months prior to screening and/or subjects with a positive blood test for tuberculosis at screening. Subjects with high risk of latent tuberculosis (e.g. prior residence in or travel to countries with high prevalence of tuberculosis, close contact with a person with active tuberculosis, or a history of active or latent tuberculosis where an adequate course of treatment cannot be confirmed) must have been tested at screening.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Delgocitinib cream 20 mg/g

    Delgocitinib cream applied twice daily for 6 weeks

    Drug: Delgocitinib cream

  • Placebo comparator
    Delgocitinib cream vehicle

    Delgocitinib cream vehicle applied twice daily for 6 weeks

    Drug: Delgocitinib cream vehicle

Interventions

  • Cream for topical application.

    Also known as: LEO 124249 cream

  • DrugDelgocitinib cream vehicle

    The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.

    Also known as: LEO 124249 cream vehicle

06

What researchers measure

Primary outcomes

  1. Target Lesions With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 6.

    The IGA is an instrument used in clinical trials to rate the severity of the subject's global disease and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). In this trial, the IGA was a lesion-specific assessment and was evaluated separately for each of the 2 target lesions.

    Time frame: Week 6

Secondary outcomes

  1. Number of Adverse Events (AEs) up to Week 6.

    Number of AEs from baseline to Week 6

    Time frame: Week 0 to Week 6

  2. Number of Subjects With AEs up to Week 6.

    Number of subjects with AEs from baseline to Week 6

    Time frame: Week 0 to Week 6

  3. Number of Lesion-specific, Treatment-related AEs up to Week 6.

    The number of lesion-specific, treatment-related AEs per target lesion will be compared for active and vehicle treatment. Lesion-specific AEs are defined as lesional/perilesional AEs (i.e. AE location within the treatment area and/or ≤2 cm from the border of a target lesion).

    Time frame: Week 0 to Week 6

  4. Number of Lesions With ≥2-point Reduction in IGA Score at Week 6 Compared to Baseline.

    The IGA is an instrument used in clinical trials to rate the severity of the subject's global disease and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). In this trial, the IGA was a lesion-specific assessment and was evaluated separately for each of the 2 target lesions.

    Time frame: Week 0 to Week 6

  5. Number of Lesions With ≥2-point Reduction in Erythema Score at Week 6 Compared to Baseline.

    The erythema score is lesion-specific and based on the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) and the Revised CLASI (RCLASI) which are validated scoring systems to assess disease activity and damage in patients with cutaneous lupus erythematosus. The severity of the erythema is scored on a 4-point scale ranging from 0 to 3. The severity is scored from low to high with 0=absent and 3=dark red, purple/violaceous/crusted/haemorrhagic.

    Time frame: Week 0 to Week 6

  6. Erythema Score at Week 6.

    The erythema score is lesion-specific and based on the CLASI and the RCLASI which are validated scoring systems to assess disease activity and damage in patients with cutaneous lupus erythematosus. The severity of the erythema is scored on a 4-point scale ranging from 0 to 3. The severity is scored from low to high with 0=absent and 3=dark red, purple/violaceous/crusted/haemorrhagic.

    Time frame: Week 6

  7. Total Skin Disease Activity Score (Sum of Scores for Erythema, Scaling/Hyperkeratosis, and Oedema/Infiltration) at Week 6.

    The skin disease activity scores are based on the CLASI and the RCLASI which are validated scoring systems to assess disease activity and damage in patients with cutaneous lupus erythematosus. The total skin disease activity score is defined as the sum of the scores for 3 clinical signs (erythema, scaling/hyperkeratosis, oedema/infiltration) for each target lesion. For the total score and the individual clinical signs, higher scores indicate more severe symptoms. Erythema is scored on a 4-point scale ranging from 0 (absent) to 3 (dark red, purple/violaceous/crusted/haemorrhagic). Hyperkeratosis/scaling is scored on a 3-point scale from 0 (absent) to 2 (verrucous hyperkeratosis). Oedema/infiltration is scored on a 3-point scale from 0 (absent) to 2 (palpable and visible). The total skin disease activity score can therefore range from 0 to 7.

    Time frame: Week 6

07

Results

Posted Jun 28, 2021
Limitations and caveats
The trial was terminated prematurely due to slow recruitment, and due to an anticipation that recruitment would become further delayed due to the COVID-19 pandemic affecting recruitment activities. The total number of subjects included in the trial therefore ended with 27 subjects randomised. 26 subjects completed the trial, as 1 subject withdrew from the trial due to an AE (moderate cutaneous lupus erythematosus \[CLE\]; reported term: cutaneous lupus erythematosus flare).

Participant flow

37 subjects screened. 27 subjects randomised. 26 subjects completed.

Participant flow — Overall Study
MilestoneAll Subjects
Started27
Lesions treated with delgocitinib cream27
Lesions treated with delgocitinib cream vehicle27
Completed26
Not completed1
Withdrew: Adverse event1

Outcome measures

PrimaryTarget Lesions With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 6.

The IGA is an instrument used in clinical trials to rate the severity of the subject's global disease and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). In this trial, the IGA was a lesion-specific assessment and was evaluated separately for each of the 2 target lesions.

Time frame:
Week 6
Reported as:
Number · lesions
Target Lesions With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 6.
lesionsDelgocitinib Cream 20 mg/gDelgocitinib Cream Vehicle
Target Lesions With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 6.36
Statistical analysis
  • Delgocitinib Cream 20 mg/g vs Delgocitinib Cream Vehicle · McNemar · p = 0.4531 (Exact p-value of McNemar's test.) · Attributable risk: -0.14 · 95% CI -0.37 to 0.09Attributable risk is defined as the difference in estimated probability of treatment success of delgocitinib compared to vehicle. Exact p-value of McNemar's test. Success is defined as having an IGA score of 0 (clear) or 1 (almost clear) at Week 6.
SecondaryNumber of Adverse Events (AEs) up to Week 6.

Number of AEs from baseline to Week 6

Time frame:
Week 0 to Week 6
Reported as:
Number · AEs
Number of Adverse Events (AEs) up to Week 6.
AEsAll Subjects
Number of Adverse Events (AEs) up to Week 6.8
SecondaryNumber of Subjects With AEs up to Week 6.

Number of subjects with AEs from baseline to Week 6

Time frame:
Week 0 to Week 6
Reported as:
Count of participants · Participants
Number of Subjects With AEs up to Week 6.
ParticipantsAll Subjects
Number of Subjects With AEs up to Week 6.8
SecondaryNumber of Lesion-specific, Treatment-related AEs up to Week 6.

The number of lesion-specific, treatment-related AEs per target lesion will be compared for active and vehicle treatment. Lesion-specific AEs are defined as lesional/perilesional AEs (i.e. AE location within the treatment area and/or ≤2 cm from the border of a target lesion).

Time frame:
Week 0 to Week 6
Reported as:
Number · AEs
Number of Lesion-specific, Treatment-related AEs up to Week 6.
AEsDelgocitinib Cream 20 mg/gDelgocitinib Cream Vehicle
Number of Lesion-specific, Treatment-related AEs up to Week 6.20
Statistical analysis
  • Delgocitinib Cream 20 mg/g vs Delgocitinib Cream Vehicle · McNemar · p = 0.5000 (Exact p-value of McNemar's test.) · Attributable risk: 0.07 · 95% CI -0.02 to 0.17Attributable risk is defined as the difference in estimated probability of treatment success (i.e. no lesion-specific treatment-related AEs) of delgocitinib compared to vehicle. Exact p-value of McNemar's test.
SecondaryNumber of Lesions With ≥2-point Reduction in IGA Score at Week 6 Compared to Baseline.

The IGA is an instrument used in clinical trials to rate the severity of the subject's global disease and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). In this trial, the IGA was a lesion-specific assessment and was evaluated separately for each of the 2 target lesions.

Time frame:
Week 0 to Week 6
Reported as:
Number · lesions
Number of Lesions With ≥2-point Reduction in IGA Score at Week 6 Compared to Baseline.
lesionsDelgocitinib Cream 20 mg/gDelgocitinib Cream Vehicle
Number of Lesions With ≥2-point Reduction in IGA Score at Week 6 Compared to Baseline.36
Statistical analysis
  • Delgocitinib Cream 20 mg/g vs Delgocitinib Cream Vehicle · McNemar · p = 0.4531 (Exact p-value of McNemar's test.) · Attributable risk: -0.14 · 95% CI -0.37 to 0.09Attributable risk is defined as the difference in estimated probability of treatment success of delgocitinib vs vehicle. Exact p-value of McNemar's test. Success is defined as having at least a 2-point reduction in IGA score from baseline to Week 6.
SecondaryNumber of Lesions With ≥2-point Reduction in Erythema Score at Week 6 Compared to Baseline.

The erythema score is lesion-specific and based on the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) and the Revised CLASI (RCLASI) which are validated scoring systems to assess disease activity and damage in patients with cutaneous lupus erythematosus. The severity of the erythema is scored on a 4-point scale ranging from 0 to 3. The severity is scored from low to high with 0=absent and 3=dark red, purple/violaceous/crusted/haemorrhagic.

Time frame:
Week 0 to Week 6
Reported as:
Number · lesions
Number of Lesions With ≥2-point Reduction in Erythema Score at Week 6 Compared to Baseline.
lesionsDelgocitinib Cream 20 mg/gDelgocitinib Cream Vehicle
Number of Lesions With ≥2-point Reduction in Erythema Score at Week 6 Compared to Baseline.55
Statistical analysis
  • Delgocitinib Cream 20 mg/g vs Delgocitinib Cream Vehicle · McNemar · p = 1.0000 (Exact p-value of McNemar's test.) · Attributable risk: 0.00 · 95% CI -0.22 to 0.22
SecondaryErythema Score at Week 6.

The erythema score is lesion-specific and based on the CLASI and the RCLASI which are validated scoring systems to assess disease activity and damage in patients with cutaneous lupus erythematosus. The severity of the erythema is scored on a 4-point scale ranging from 0 to 3. The severity is scored from low to high with 0=absent and 3=dark red, purple/violaceous/crusted/haemorrhagic.

Time frame:
Week 6
Reported as:
Median · scores on a scale
Erythema Score at Week 6.
scores on a scaleDelgocitinib Cream 20 mg/gDelgocitinib Cream Vehicle
Erythema Score at Week 6.1.5 (1 to 2)1.5 (1 to 2)
Statistical analysis
  • Delgocitinib Cream 20 mg/g vs Delgocitinib Cream Vehicle · Wilcoxon signed rank test · p = 0.5797 (P-value of the Wilcoxon signed rank test.)Erythema is scored as 0=absent, 1=pink, faint, 2=red, 3=dark red, purple/violaceous/crusted/haemorrhagic. P-value of the Wilcoxon signed rank test.
SecondaryTotal Skin Disease Activity Score (Sum of Scores for Erythema, Scaling/Hyperkeratosis, and Oedema/Infiltration) at Week 6.

The skin disease activity scores are based on the CLASI and the RCLASI which are validated scoring systems to assess disease activity and damage in patients with cutaneous lupus erythematosus. The total skin disease activity score is defined as the sum of the scores for 3 clinical signs (erythema, scaling/hyperkeratosis, oedema/infiltration) for each target lesion. For the total score and the individual clinical signs, higher scores indicate more severe symptoms. Erythema is scored on a 4-point scale ranging from 0 (absent) to 3 (dark red, purple/violaceous/crusted/haemorrhagic). Hyperkeratosis/scaling is scored on a 3-point scale from 0 (absent) to 2 (verrucous hyperkeratosis). Oedema/infiltration is scored on a 3-point scale from 0 (absent) to 2 (palpable and visible). The total skin disease activity score can therefore range from 0 to 7.

Time frame:
Week 6
Reported as:
Median · scores on a scale
Total Skin Disease Activity Score (Sum of Scores for Erythema, Scaling/Hyperkeratosis, and Oedema/Infiltration) at Week 6.
scores on a scaleDelgocitinib Cream 20 mg/gDelgocitinib Cream Vehicle
Total Skin Disease Activity Score (Sum of Scores for Erythema, Scaling/Hyperkeratosis, and Oedema/Infiltration) at Week 6.2.5 (2 to 4)2.5 (1 to 4)
Statistical analysis
  • Delgocitinib Cream 20 mg/g vs Delgocitinib Cream Vehicle · Wilcoxon signed rank test · p = 0.7862 (P-value of the Wilcoxon signed rank test.)P-value of the Wilcoxon signed rank test.

Adverse events

Collected over 8 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Subjects0/27 (0%)0/27 (0%)10/27 (37%)
Most frequent other events
Most frequent other events
EventAll Subjects
NasopharyngitisInfections and infestations4/27
Cutaneous lupus erythematosusSkin and subcutaneous tissue disorders1/27
Rash erythematousSkin and subcutaneous tissue disorders1/27
Middle ear inflammationEar and labyrinth disorders1/27
Gastrointestinal disorderGastrointestinal disorders1/27
Application site painGeneral disorders1/27
Application site pruritusGeneral disorders1/27
Musculoskeletal painMusculoskeletal and connective tissue disorders1/27
HeadacheNervous system disorders1/27

Baseline characteristics

Randomised subjects

Age, Continuous
Age, Continuous(years)All Randomised Subjects
Mean45.7 ± 13.4
Sex: Female, Male
Sex: Female, Male(Participants)All Randomised Subjects
Female15
Male12
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Randomised Subjects
Hispanic or Latino2
Not Hispanic or Latino24
Unknown or Not Reported1
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Randomised Subjects
Race — Black or African American2
Race — White20
Race — Other4
Race — Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(participants)All Randomised Subjects
United States4
Denmark1
France5
Germany17
Investigator's Global Assessment (IGA) of lesions to be treated with delgocitinib cream
Investigator's Global Assessment (IGA) of lesions to be treated with delgocitinib cream(percentage of lesions)All Randomised Subjects
IGA score 3 (moderate)88.9
IGA score 4 (severe)11.1
Investigator's Global Assessment (IGA) of lesions to be treated with vehicle
Investigator's Global Assessment (IGA) of lesions to be treated with vehicle(percentage of lesions)All Randomised Subjects
IGA score 3 (moderate)88.9
IGA score 4 (severe)11.1
Baseline erythema score of lesions to be treated with delgocitinib cream
Baseline erythema score of lesions to be treated with delgocitinib cream(percentage of lesions)All Randomised Subjects
Erythema score 237.0
Erythema score 363.0

3 further baseline measures are reported on the registry.

08

Study locations

19 sites
  • LEO Pharma Investigational Site
    San Diego, California 92103, United States
  • LEO Pharma Investigational Site
    Skokie, Illinois 60077, United States
  • LEO Pharma Investigational Site
    Boston, Massachusetts 02115, United States
  • LEO Pharma Investigational Site
    Forest Hills, New York 11375, United States
  • LEO Pharma Investigational Site
    Cincinnati, Ohio 45219, United States
  • LEO Pharma Investigational Site
    Aarhus, 8200, Denmark
  • LEO Pharma Investigational site
    Hellerup, 2900, Denmark
  • LEO Pharma Investigational Site
    Odense, 5000, Denmark
  • LEO Pharma Investigational Site
    Loiré, 42000, France
  • LEO Pharma Investigational Site
    Nice, 06202, France
  • LEO Pharma Investigational Site
    Paris, 75010, France
  • LEO Pharma Investigational Site
    Toulouse, 31000, France
  • LEO Pharma Investigational Site
    Aachen, 52074, Germany
  • LEO Pharma Investigational Site
    Berlin, 10117, Germany
  • LEO Pharma Investigational Site
    Bochum, 44791, Germany
  • LEO Pharma Investigational Site
    Dresden, 01307, Germany
  • LEO Pharma Investigational Site
    Duesseldorf, 40225, Germany
  • LEO Pharma Investigational Site
    Erlangen, 91054, Germany
  • LEO Pharma Investigational Site
    Oldenburg, 26133, Germany
09

References and documents

Publications

  • Hannon CW, McCourt C, Lima HC, Chen S, Bennett C. Interventions for cutaneous disease in systemic lupus erythematosus. Cochrane Database Syst Rev. 2021 Mar 9;3(3):CD007478. doi: 10.1002/14651858.CD007478.pub2. PubMed 33687069 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2019 to primary completion in Apr 2020, 9 months.

Results were first posted in Jun 2021, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2019
First posted
May 22, 2019
StartActual
Jul 9, 2019
Primary completionActual
Apr 15, 2020
CompletionActual
Apr 30, 2020
Results first posted
Jun 28, 2021
Last update
Mar 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03958955
Lead sponsor
LEO Pharma
Responsible party
Sponsor
First posted
May 22, 2019
Start date
Jul 9, 2019
Primary completion
Apr 15, 2020
Completion
Apr 30, 2020
Results posted
Jun 28, 2021
Last update
Mar 6, 2025

Study contacts

Medical Expert
study director · LEO Pharma

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Delgocitinib

Start the discussion